An interventional study of Virtual Reality Gamma Sensory Stimulation and Virtual Reality Sham Sensory Stimulation in Multiple Sclerosis, sponsored by Clarity Health Technologies, Inc. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Clarity Health Technologies, Inc · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 230 studies in Multiple Sclerosis with a site in Spain — 35 open to participants now, 56 under way, 14 of them phase 3. Multiple Sclerosis · Spain.
Among the 230 studies in Multiple Sclerosis with a site in Spain, this one is the 158th largest by planned enrollment of the 202 interventional ones that give a count, is one of 12 that started in 2026, is one of 68 with no phase, reaches primary completion later than 35 of the 55 other live ones, and was the 216th registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →35 of the 230 studies in Multiple Sclerosis with a site in Spain are open now. Recruiting first, the newest first:
Sanofi · Sites in Spain, United States, Belgium and 4 more countries
Ages 18–60
Novartis Pharmaceuticals · Sites in Spain, United States, Argentina and 33 more countries
Ages 18–65
Hasselt University · Sites in Spain, Belgium, Italy
Ages 18–65 · Healthy volunteers
Hoffmann-La Roche · Sites in Spain, Argentina, Brazil and 4 more countries
Ages 10–17
University of Vigo · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
230 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 47 · Phase 3 65 · Phase 4 17
First in 2002; this study’s year is marked. 12 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.
Median enrollment 137 across the 202 interventional studies, 360 across the 28 observational. Of the 163 that completed or were terminated, 80 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
142 of 230 have an industry lead sponsor. The 10 most frequent:
Clarity Health Technologies, Inc is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Clarity Health Technologies, Inc has 1 study filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
13 of the studies in Multiple Sclerosis with a site in Spain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT07325292Phase 3SanofiNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis | 2027-07-15 |
| NCT07735325University of SalamancaEffects of Sensorimotor Insoles on Stability and Gait in Patients With Multiple Sclerosis. | 2026-12 |
| NCT07152145Parc de Salut MarPilot Study of tSCS for Improving Upper Limb Function in People With Multiple Sclerosis | 2026-12 |
| NCT06968676Universidad Rey Juan CarlosMixed Reality for Upper Limb Rehabilitation in People With Multiple Sclerosis (VIRTUALDOMUS) | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 230 studies in Multiple Sclerosis with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a double-blind, parallel, randomized, sham-controlled pilot study evaluating the safety, feasibility, and efficacy of Gamma Sensory Stimulation (GSS) delivered via a Virtual Reality (VR) headset in individuals with Multiple Sclerosis (MS) who experience moderate to severe fatigue. Participants will be randomized (1:1) to 4 weeks of active GSS or sham stimulation, followed by a 4-week post-treatment follow-up. The primary objective is to determine whether GSS reduces fatigue, measured by the Modified Fatigue Impact Scale (MFIS). Secondary outcomes include additional fatigue scales, cognitive performance, quality-of-life measures, tolerability and safety.
Gamma Sensory Stimulation (GSS) is a non-invasive audiovisual neuromodulation method that delivers synchronized 40 Hz stimulation to engage gamma-band neural oscillations. Gamma-frequency activity is implicated in cognitive processing and large-scale network coordination, which may be disrupted in people with Multiple Sclerosis (MS), particularly in those experiencing fatigue. Prior research suggests that gamma-frequency entrainment may modulate neural network activity and support functional outcomes.
This single-center, double-blind, randomized, sham-controlled pilot study investigates whether 4 weeks of GSS delivered through an immersive Virtual Reality (VR) system can reduce fatigue in individuals with MS. Participants with moderate to severe fatigue will be randomized in a 1:1 ratio to receive either active GSS or sham stimulation embedded in matched VR content. The intervention consists of 16 in-lab stimulation sessions delivered over 4 weeks (4 sessions per week). Each session includes 30 minutes of active stimulation within a standardized VR experience.
The primary endpoint is the change in Modified Fatigue Impact Scale (MFIS) total score from baseline to End of Treatment (Week 4). Secondary endpoints include changes from baseline to End of Treatment (Week 4) and follow-up (Week 8) in additional validated fatigue measures (Fatigue Severity Scale, Visual Analogue Scale for Mental Fatigue, PROMIS Fatigue), cognitive performance assessed by the Symbol Digit Modalities Test (SDMT), quality-of-life measures (Neuro-QoL Fatigue), and the rate of change in Daily Fatigue Severity (DFS) across the treatment period. Exploratory outcomes include MFIS subscale scores, variability in daily fatigue ratings, embedded cognitive task performance during stimulation, and treatment acceptability.
Safety and tolerability will be assessed through monitoring of adverse events, session attendance, and retention. Electroencephalography (EEG) will be collected at baseline and at End of Treatment (Week 4) for exploratory characterization of neural responses to gamma-frequency stimulation.
This pilot investigation aims to generate preliminary safety, feasibility, and efficacy data to inform future multisite studies evaluating VR-based GSS as a potential at-home therapeutic approach for MS-related fatigue.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Based on the investigator's judgment, the subject should:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive Gamma Sensory Stimulation delivered through a virtual reality (VR) headset and headphones. Stimulation sessions last 30 minutes and are delivered four times per week for four weeks within standardized, engaging VR environments.
Device: Virtual Reality Gamma Sensory Stimulation
Participants receive sham sensory stimulation delivered through a virtual reality (VR) headset and headphones. Sessions last 30 minutes and are delivered four times per week for four weeks within the same VR environments used in the active intervention.
Device: Virtual Reality Sham Sensory Stimulation
Participants receive 30 minutes of Gamma Sensory Stimulation delivered through a virtual reality (VR) headset and headphones. Visual and auditory stimulation parameters are configured to deliver rhythmic sensory stimulation intended to engage gamma-band neural activity. Sessions occur four times per week for four weeks and are embedded within standardized VR environments.
Also known as: 40 Hz sensory stimulation, 40 Hz audiovisual stimulation, Gamma flickers, 40Hz flickers, VR-GSS
Participants receive 30 minutes of sham sensory stimulation delivered through a virtual reality (VR) headset and headphones. The sham intervention uses identical VR environments, session duration, and procedures as the active intervention, providing an equivalent participant experience without delivering therapeutic stimulation. Sessions occur four times per week for four weeks.
Also known as: sham sensory stimulation, sham VR-GSS
Change in Modified Fatigue Impact Scale (MFIS) total score
The Modified Fatigue Impact Scale (MFIS) is a 21-item patient-reported outcome assessing the impact of fatigue on physical, cognitive, and psychosocial functioning. Scores range from 0 to 84, with higher scores indicating greater fatigue impact. This outcome measures the change in MFIS total score from baseline to Week 4. Negative change values represent improvement in fatigue.
Time frame: Baseline to End of Treatment (week 4)
Change in MFIS at Follow up
MFIS is a 21-item patient-reported fatigue impact scale (range 0-84; higher scores indicate greater fatigue). This outcome assesses change in total MFIS score from baseline to follow-up assessment (Week 8).
Time frame: Baseline to Follow-up (week 8)
Change in Fatigue Severity Scale (FSS)
The Fatigue Severity Scale (FSS) is a 9-item questionnaire assessing the severity and functional impact of fatigue on daily activities. Each item is scored 1-7; the final score is the mean of all items, with higher scores indicating more severe fatigue. This outcome reflects change in FSS score from baseline to Week 4 and Week 8.
Time frame: Baseline to End of Treatment (week 4) and Follow-up (week 8)
Change in Visual Analogue Scale for Mental Fatigue (VAS-MF)
VAS-MF is a single-item 0-100 mm visual analogue scale measuring perceived mental fatigue. Higher values indicate greater fatigue. This outcome assesses change in VAS-MF score from baseline to Week 4 and Week 8
Time frame: Baseline to End of Treatment (week 4) and Follow-up (week 8)
Change in PROMIS Fatigue Score
The PROMIS Fatigue Short Form assesses self-reported fatigue and its interference with daily functioning. Scores are reported as standardized T-scores (mean 50, SD 10); higher scores indicate greater fatigue. This outcome measures change in PROMIS Fatigue from baseline to Week 4 and Week 8.
Time frame: Baseline to End of Treatment (week 4) and Follow-up (week 8)
Change in Neuro-QoL Fatigue
Neuro-QoL Fatigue evaluates the impact of fatigue on quality of life in neurological conditions. Scores are converted to T-scores (mean 50, SD 10), with higher scores indicating worse fatigue-related QoL. This outcome measures change in Neuro-QoL Fatigue from baseline to Week 4 and Week 8
Time frame: Baseline to End of Treatment (week 4) and Follow-up (week 8)
Change in Symbol Digit Modalities Test (SDMT)
The SDMT is a widely used measure of information processing speed. The score reflects the number of correct symbol-digit matches completed in 90 seconds, with higher scores indicating better cognitive performance. This outcome assesses change in SDMT score from baseline to Week 4 and Week 8.
Time frame: Baseline to End of Treatment (week 4) and Follow-up (week 8)
Rate of Change in Daily Fatigue Severity (DFS) During the Treatment Period
Daily Fatigue Severity (DFS) is assessed using a repeated self-reported rating of fatigue severity. Participants respond to the question "How fatigued do you feel today?" using a 7-point Likert scale, where higher scores indicate greater fatigue. This outcome assesses the rate of change in DFS across the treatment period to characterize longitudinal changes in daily fatigue.
Time frame: Baseline through End of treatment (week 4)
Change in MFIS Subscale Scores (Physical, Cognitive, Psychosocial)
The MFIS yields three subscale scores assessing physical, cognitive, and psychosocial fatigue impact. Higher scores indicate greater impairment. This outcome measures change in each subscale from baseline to Week 4 and Week 8.
Time frame: Baseline to End of Treatment (week 4) and Follow-up (week 8)
Cognitive Performance During Stimulation (Embedded Virtual Reality Tasks)
Cognitive performance is assessed using tasks embedded within the virtual reality environment during stimulation sessions. These tasks are designed to probe attention, processing speed, and learning dynamics while participants receive either active or sham stimulation. Performance data collected across sessions will be used for exploratory analyses of cognitive performance and learning trajectories during the treatment period.
Time frame: Baseline through End of Treatment (week 4)
Treatment Acceptability Ratings
Longitudinal acceptability is evaluated at Weeks 2, 4 and 8 by asking participants about their willingness to use the device at home as a future treatment for MS-related fatigue. Responses provide insight into perceived usability, tolerability, and overall acceptability of the intervention over time.
Time frame: Week 2, Week 4, and Week 8
Incidence of Adverse Events (AEs)
AEs are defined as any unfavorable medical occurrence during the study, whether or not considered related to the intervention. Events are categorized by severity and relationship to study treatment. This outcome measures the proportion of participants experiencing at least one AE.
Time frame: Baseline through Follow-up (week 8)
Incidence of Serious Adverse Events (SAEs)
SAEs include events resulting in hospitalization, persistent disability, life-threatening conditions, or death. This outcome reports the number and proportion of participants experiencing SAEs during the study.
Time frame: Baseline through Week 8
Tolerability: Session Attendance / Adherence Rate
Tolerability is assessed through adherence to the prescribed stimulation schedule. This outcome measures the percentage of completed sessions out of the total required (16 sessions delivered over 4 weeks).
Time frame: Weeks 0-4
Study Retention Rate
Retention rate is defined as the proportion of participants who complete the follow-up assessment (week 8) relative to those enrolled.
Time frame: Baseline through Follow-up (week 8)
Events of Clinical Interest (Agitation/Confusion)
Events of clinical interest include agitation, confusion, or disorientation occurring within 1 hour of stimulation. This outcome captures their incidence and severity.
Time frame: Immediately monitored following stimulation; Through Week 4
Plan to share: No — This study collects pseudonymized clinical, behavioral, and EEG data that are subject to GDPR and local data protection regulations. Because the dataset contains sensitive information that cannot be fully de-identified, individual-level data will not be made publicly available. Aggregate results may be shared in publications or upon reasonable request to the sponsor.
Started Aug 2026 (actual). Primary completion is estimated for Jun 2027, 10 months after the start.
Of 874 interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 10 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: start Mar 2026 → Aug 2026, primary completion Mar 2027 → Jun 2027 and completion Apr 2027 → Aug 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Clarity Health Technologies, Inc